Prostaglandins in the patent literature

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 9, 2007, Pages 1131-1145

  Ebenezar, Kesavarao K ^a   Smith, Francine G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Agonist; Analog; Antagonist; Cyclooxygenase enzymes; Prostaglandins; Receptors; Vasodilation

Indexed keywords

1 ACYLOXY 15 DEOXY 16 HYDROXY; BENZENE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CYCLOALKANOL DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; CYCLOPENTANONE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; ICOSANOID; METHANOL DERIVATIVE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOIC ACID; PROSTANOID; PROSTANOID RECEPTOR; PYRIDINE DERIVATIVE; THROMBOXANE A2; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; ARTERIOSCLEROSIS; ATHEROGENESIS; BRONCHOSPASM; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SYNTHESIS; GLAUCOMA; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERTENSION; INTRAOCULAR HYPERTENSION; NONHUMAN; PATENT; PROSTAGLANDIN SYNTHESIS; PULMONARY HYPERTENSION; REVIEW; SEXUAL DYSFUNCTION; SMOOTH MUSCLE CONTRACTION; STOMACH DISEASE; THROMBOCYTE AGGREGATION; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VASODILATATION;

EID: 35348963578     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.9.1131     Document Type: Review

References (117)

1. LYDFORD SJ, MCKECHNIE KC, LEFF P: Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein. Prostaglandins (1996) 52(2):125-139.
2. MURAKAMI M, NAKATANI Y, ATSUMI G, INOUE K, KUDO I: Regulatory functions of phospholipase A2. Crit. Rev. Immunol. (1997) 17(3-4):225.
3. MURAKAMI M, KUDO I: Phospholipase A2. J. Biochem. (Tokyo) (2002) 131(3):285-292.
4. HAMBERG M, SVENSSON J, SAMUELSSON B: Prostaglandin endoperoxides. A new concept concerning the mode of action and release of Prostaglandins. Proc. Natl. Acad. Sci. USA (1974) 71:3824-3828.
5. BREYER MD, BREYER RM: Prostaglandin receptors: their role in regulating renal function. Curr. Opin. Nephrol. Hypertens. (2000) 9(1):23-29.
6. FUNK C, FURCHI L, FITZGERALD G et al.: Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem. (1993) 268(35):26767-26772.
7. VANE JR, BAKHLE YS, BOTTING RM: Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol. (1998) 38:97-120.
8. COLEMAN RA, SMITH WL, NARUMIYA S: International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. (1994) 46(2):205-229.
9. O'NEILL GP, FORD-HUTCHINSON AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. (1993) 330(2):156-160.
10. JONES RL, WILSON NH, MARR CG, MUIR G, ARMSTRONG RA: Diphenylmethylazine prostanoids with prostacyclin-like actions on human platelets. J. Lipid Mediat. (1993) 6(1-3):405-410.
11. CROFFORD LJ, WILDER RL, RISTIMAKI AP et al.: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 β, phorbolester, and corticosteroids. J. Clin. Invest. (1994) 93(3):1095-1101.
12. AGRO A, LANGDON C, SMITH F, RICHARDS CD: Prostaglandin E2 enhances interleukin 8 (IL-8): and IL-6 but inhibits GMCSF production by IL-1 stimulated human synovial fibroblasts in vitro. J. Rheumatol. (1996) 23(5):862-868.
13. CHANDRASEKHARAN NV, DAI H, ROOS KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA (2002) 99(21):13926-13931.
14. NARUMIYA S: Prostanoid receptors. Structure, function and distribution. Ann. NY Acad. Sci. (1994) 744:126-138.
15. SMITH WL, LANGENBACH R: Why there are two cyclooxygenase isozymes. J. Clin. Invest. (2001) 107(12):1491-1495.
16. FUNK CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (2001) 294(5548):1871-1875.
17. KANAI N, LU R, SATRIANO JA, BAO Y, WOLKOFF AW, SCHUSTER VL: Identification and characterization of a prostaglandin transporter. Science (1995) 268(5212):866-869.
18. TAI HH, ENSOR CM, TONG M, ZHOU H, YAN F: Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. (2002) 68-69:483-493.
19. OATES JA, FITZGERALD GA, BRANCH RA, JACKSON EK, KNAPP HR, ROBERTS LJ II: Clinical implications of prostaglandin and thromboxane A2 formation (2). N. Engl. J. Med. (1988) 319(12):761-767.
20. CASTELLANI S, PALADINI B, PANICCIA R et al.: Increased renal formation of thromboxane A2 and prostaglandin F2 α in heart failure. Am. Heart J. (1997) 133(1):94-100.
21. SPURNEY RF, FAN PY, RUIZ P, SANFILIPPO F, PISETSKY DS, COFFMAN TM: Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. Kidney Int. (1992) 41(4):973-982.
22. MORINELLI TA, TEMPEL GE, JAFFA AA et al.: Thromboxane A2/ prostaglandin H2 receptors in streptozotocin-induced diabetes: effects of insulin therapy in the rat. Prostaglandins (1993) 45(5):427-438.
23. MURATA T, USHIKUBI F, MATSUOKA T et al.: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 388(6643):678-682.
24. TUDER RM, COOL CD, GERACI MW et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. (1999) 159(6):1925-1932.
25. MONCADA S, GRYGLEWSKI R, BUNTING S, VANE JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 263(5579):663-665.
26. BOLGER PM, EISNER GM, RAMWELL PW, SLOTKOFF LM: Renal actions of prostacyclin. Nature (1978) 271(5644):467.
27. EDWARDS RM: Efleccs of Prostaglandins on vasoconstrictor action in isolated renal arterioles. Am. J. Physiol. (1985) 248(6 Part 2):F779-F784.
28. ITO S, CARRETERO OA, ABE K, BEIERWALTES WH, YOSHINAGA K: Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int. (1989) 35(5):1138-1144.
29. BUGGE JF, STOKKE ES, VIKSE A, KIIL F: Stimulation of renin release by PGE2 and PG12 infusion in the dog: enhancing effect of ureteral occlusion or administration of ethacrynic acid. Acta Physiol. Scand.(1990) 138(2):193-201.
30. ITO S, NARUMIYA S, HAYAISHI O: Prostaglandin D2: a biochemical perspective. Prostaglandins Leukot. Essent. Fatty Acids (1989) 37(4):219-234.
31. ITO S, OKUDA E, SUGAMA K, NEGISHI M, HAYAISHI O: Evaluation of ZK110841 and AH6809, an agonist and an antagonist of prostaglandin DP receptors on human platelets, with a PGD2-responsive cell line from bovine embryonic trachea. Br. J. Pharmacol. (1990) 99(1):13-14.
32. LEFF P, GILES H: Classification of platelet and vascular prostaglandin D2 (DP) receptors: estimation of affinities and relative efficacies for a series of novel bicyclic ligands. With an appendix on goodness-of-fit analyses. Br. J. Pharmacol. (1992) 106(4):996-1003.
33. WILSON TW, KAUSHAL RD, DUBOIS M: Prostaglandins, the kidney, and hypertension. West J. Med. (1990) 153(2):168-172.
34. BREYER RM, BAGDASSARIAN CK, MYERS SA, BREYER MD: Prostanoid receptors: subtypes and signaling. Ann. Rev. Pharmacol. Toxicol. (2001) 41:661-690.
35. NARUMIYA S, SUGIMOTO Y, USHIKUBI F: Prostanoid receptors: structures, properties and functions. Physiol. Rev. (1999) 79(4):1193-1226.
36. NARUMIYA S: Prostanoid receptors. Structure, function and distribution. Ann. NY Acad. Sci. (1994) 744:126-138.
37. SUGAMA K, TANAKA T, YOKOHAMA H et al.: Stimulation of cAMP formation by prostaglandin D2 in primary cultures of bovine adrenal medullary cells: identification of the responsive population as fibroblasts. Biochim. Biophys. Acta (1989) 1011(1):75-80.
38. NAMBA T, OIDA H, SUGIMOTO Y et al.: cDNA cloning of a mouse prostacyclin receptor; multiple signalling pathways and expression in thymic medufla. J. Biol. Chem. (1994) 269(13):9986-9992.
39. BOIE Y, SAWYER N, SLIPETZ DM, METTERS KM, ABRAMOVITZ M: Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. (1995) 270(32):18910-18916.
40. TOH H, ICHIKAWA A, NARUMIYA S: Molecular evolution of receptors for eicosanoids. FEBS Lett. (1995) 361(1):17-21.
41. COLEMAN RA, KENNEDY I, HUMPHREY PPA, BUNCE K, LUMLEY P: Prostanoids and their receptors. In: Comprehensive Medicinal Chemistry (Volume 3). Membranes and receptors. Emmett JC (Ed.), Pergamon Press, Oxford, UK (1990):643-714.
42. HONDA A, SUGIMOTO Y, NAMBA T et al.: Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem. (1993) 268(11):759-7762.
43. WATABE A, SUGIMOTO Y, HONDA A et al.: Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J. Biol. Chem. (1993) 268(27):20175-20178.
44. ABRAMOVITZ M, ADAM M, BOIE Y et al.: Human prostanoid: cloning and characterization. Adv. Prostaglandin Thromboxane Leukot. Res. (1995) 23:499-504.
45. + absorption by activating the EP1 receptor. J. Clin. Invest. (1998) 102(1):194-201.
46. REGAN JW, BAILEY TJ, PEPPERL DJ et al.: Cloning of a novel human prostaglandin receptor with characteristics of pharmacologically defined EP2 subtype. Mol. Pharmacol. (1994) 46(2):213-220.
47. KATSUYAMA M, NISHIGAKI N, SUGIMOTO Y et al.: The mouse prostaglandin E receptor EP2 subtype: cloning, expression and northern blot analysis. FEBS Lett. (1995) 372(2-3):151-156.
48. GUAN Y, ZHANG YH, STILLMAN BA et al.: Cloning and functional expression of the rabbit prostaglandin EP2 receptor. J. Am. Soc. Nephrol. (1996) 7:1646.
49. NEMOTO K, PILBEAM CC, BILAK S, RAISZ L: Molecular cloning and expression of the rat prostaglandin E2 receptor of the EP2 subtype. Prostaglandins (1997) 54(4):713-725.
50. REGAN JW, BAILEY TJ, DONELLO JE et al.: Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br. J. Pharmacol. (1994) 112(2):377-385.
51. YANG J, XIA M, GOETZL E, SONGZHU A, Cloning and expression of the EP3-subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Commun. (1994) 198(3):999-1006.
52. SCHMID A, THIERAUCH K, SCHLEUNING W, DINTER H: Splice variants of the human EP3 receptor for prostaglandin E2. Eur. J. Biochem. (1995) 228(1):23-30.
53. BASTIEN L, SAWYER N, GRYGORCZYK R, METTERS K, ADAM M: Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J. Biol. Chem. (1994) 269(16):11873-11877.
54. AN S, YANG J, XIA M, GOETZL E: Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Commun. (1993) 197(1):263-270.
55. BREYER R, DAVIS L, NIAN C et al.: Cloning and expression of the rabbit prostaglandin EP4 receptor. Am. J. Physiol. Renal. Physiol. (1996) 270 (3 Part 2):F485-F493.
56. BOIE Y, STOCCO R, SAWYWE N et al.: Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur. J. Pharmacol. (1997) 340(2-3):227-241.
57. SANDO T, USUI T, TANAKA I et al.: Molecular cloning and expression of rat prostaglandin E receptor EP2 subtype. Biochem. Biophys. Res. Commun. (1994) 200(3):1329-1333.
58. NGUYEN M, CAMENISCH T, SNOUWAERT JN et al.: The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature (1997) 390(6655):78-81.
59. SEGI E, SUGIMOTO Y, YAMASAKI A et al.: Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biachem. Biopbys. Res. Commun. (1998) 246(1):7-12.
60. HIRATA M, HAYASHI Y, USHIKUBI F et al.: Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature (1991) 349(6310):617-620.
61. BITO LZ: Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv. Ophthalmol. (1997) 41 (Suppl. 2):SI-SI4.
62. WANG RF, CAMRAS CB, LEE PY, PODOS SM, BITO LZ: Effects of Prostaglandins F2 α, A2, and their esters in glaucomatous monkey eyes. Invest. Ophthalmol. Vis. Sci. (1990) 31(11):2466-2470.
63. SUGIMOTO Y, HASUMOTO K, NAMBA T et al.: Cloning and expression of a cDNA for mouse prostaglandin F receptor. J. Biol. Chem. (1994) 269(2):1356-1360.
64. SAKAMOTO K, EZASHI T, MIWA K et al.: Molecular cloning and expression of a cDNA of the bovine prostaglandin F2 α receptor. J. Biol. Chem. (1994) 269(5):3881-3886.
65. KITANAKA J, HASIMOTO H, SUGIMOTO Y et al.: Cloning and expression of a cDNA for rat prostaglandin F2 α receptor. Prostaglandins (1994) 48(1):31-41.
66. PIERCE KL, BAILEY TJ, HOYER PB, GIL DW, WOODWARD DF, REGAN JW: Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J. Biol. Chem. (1997) 272(2):883-887.
67. SENIOR J, MARSHALL K, SANGHA R, CLAYTON JK: In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. Br. J. Pharmacol. (1993) 108(2):501-506.
68. CHEGINI N, LEI ZM, RAO CV, HANSEL W. Cellular distribution and cycle phase dependency of gonadotropin and eicosanoid binding sites in bovine corpora lutea. Biol. Reprod. (1991) 45(3):506-513.
69. BREYER MD, JACOBSON HR, DAVIS LS, BREYER RM: In situ hybridization and localization of mRNA for the rabbit prostaglandin EP3 receptor. Kidney Int. (1993) 44(6):1372-1378.
70. KIRIYAMA M, USHIKUBI F, KOBAYASHI T, HIRATA M, SUGIMOTO Y, NARUMIYA S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. (1997) 122(2):217-224.
71. OIDA H, NAMBAT, SUGIMOTO Y et al.: In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br. J. Pharmacol. (1995) 116(7):2828-2837.
72. DARIUS H, MICHAEL-HEPP J, THIERAUCH KH, FISCH A: Inhibition of human platelets and polymorphonuclear neutrophils by the potent and metabolically stable prostaglandin D2 analogue ZK 118.182. Eur. J. Pharmacol. (1994) 258(3):207-213.
73. WHEELDON A, VARDEY CJ: Characterization of the inhibitory prostanoid receptors on human neutrophils. Br. J. Pharmacol. (1993) 108(4):1051-1054.
74. ANDERSEN NH, RAMWELL PW: Biological aspects of Prostaglandins. Arch. Intern. Med. (1974) 133(1):30-50.
75. NEGISHI M, SUGIMOTO Y, ICHIKAWA A: Prostanoid receptors and their biological actions. Prog. Lipid Res. (1993) 32(4):417-434.
76. JOHNSTON SL, FREEZER NJ, RITTER W, O'TOOLE S, HOWARTH PH: Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. Eur. Respir J. (1995) 8(3):411-415.
77. MATSUGI T, KAGEYAMA M, NISHIMURA K, GILES H, SHIRASAWA E: Selective prostaglandin D2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats. Eur J. Pharmacol. (1995) 275(3):245-250.
78. CAMRAS CB, ALM A: Initial clinical studies with Prostaglandins and their analogueues. Surv. Ophthalmol. (1997) 41(Suppl. 2):S61-S68.
79. HIRATA M, KAKIZUKA A, AIZAWA M, USHIKUBI F, NARUMIYA S: Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc. Natl. Acad. Sci. USA (1994) 91(23):11192-11196.
80. MONNERET G, GRAVEL S, DIAMOND M, ROKACH J, POWELL WS: Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood (2001) 98(6):1942-1948.
81. SAWYER N, CAUCHON E, CHATEAUNEUF A et al.: Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br. J. Pharmacol. (2002) 137(8):1163-1172.
82. VANE J: Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nat. New Biol. (1971) 231(25):232-235.
83. SATOH T, ISHIKAWA Y. KATAOKA Y et al.: CNS-specific prostacyclin ligands as neuronal survival-promoting factors in the brain. Eur. J. Neurosci.(1999) 11(9):3115-3124.
84. REESE J, BROWN N, PARIA BC, MORROW J, DEY SK. COX-2 compensation in the uterus of COX-1 deficient mice during the preimplantation period. Mol. Cell. Endocrinol. (1999) 150(1-2):23-31.
85. LUQUET S, LOPEZ-SORIANO J, HOLST D et al.: Peroxisome proliferator-activated receptor δ in muscle development and oxidative capability. FASEB J. (2003) 17(15):2299-2301.
86. CHENG Y, AUSTIN SC, ROCCA B et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2, Science (2002) 296(5567):539-541.
87. WISE H, JONES RL: Focus on prostacyclin and its novel mimetics. Trends Pharmacol. Sci. (1996) 17(1):17-21.
88. VACHIERY JL, NAEIJE RT: Stable long acting prostacyclin analogue used for the treatment of pulmonary arteriolar hypertension. Expert Rev. Cardiovasc. Ther. (2004) 2(2):183-191.
89. WANG LN, TANG Z, SHOU I, FUKUI M, TOMINO Y. Effect of the PG12 analogue beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes. Nepbron (1996) 73(4):637-643.
90. EGAN KM, LAWSON JA, FRIES S et al.: COX-2 derived prostacyclin confers atheroprotection on female mice. Science (2004) 306(5704):1954-1957.
91. YOKOYAMA C, YABUKI T, SHIMONISHI M et al.: Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation (2002) 106(18):2397-2403.
92. NASRALLAH R, HEBERT RL: Prostacyclin signaling in the kidney: implications for health and disease. Am. J. Physiol Renal Physiol. (2005) 289(2):F235-F246.
93. YARED A, KON V, ICHIKAWA I: Mechanism of preservation of glomerular perfusion and filtration during acute extracellular fluid volume depletion. Importance of intrarenal vasopressin-prostaglandin interaction for protecting kidneys from constrictor action of vasopressin. J. Clin. Invest. (1985) 75(5):1477-1487.
94. BONVALET JP, PRADELLES P, FARMAN N: Segmental synthesis and actions of Prostaglandins along the nephron. Am. J. Physiol. Renal Fluid Electrolyte Physiol. (1987) 253(3 Part 2):F377-F387.
95. BAYLIS C, DEEN WM, MYERS BD, BRENNER BM: Effects of some vasodilator drugs on transcapillary fluid exchange in renal cortex. Am. J. Physiol. (1976) 230(4):1148-1158.
96. SILLDORFF EP, YANG S, PALLONE TL: Prostaglandin E2 abrogates endothelin-induced vasoconstriction in renal outer medullary descending vasa recta of the rat. J. Clin. Invest. (1995) 95(6):2734-2740.
97. BREYER M, BADR K: Arachidonic Acid Metabolites and the Kidney. Saunders, Philadelphia, USA (1996).
98. ROBERT A, NEZAMIS J, PHILLIPS J: Inhibition of gastric secretion by Prostaglandins. Am. J. Dig. Dis. (1967) 12(10):1073-1076.
99. MATUSCHANSKY C, BERNIER J: Effect of prostaglandin E1 on glucose, water and electrolyte absorption in the human jejunum. Gastroenterology (1973) 64(6):1111-1118.
100. KADOWITZ P, JOINER R HYMAN A: Influence of Prostaglandins E1 and F2 on pulmonary vascular resistance in the sheep. Proc. Soc. Exp. Biol. Med. (1974) 145(4):1258-1261.
101. MATHE A, HEDQVIST P: Effect of Prostaglandins F2 α and E2 on airway conductance in healthy subjects and asthmatic patients. Am. Rev. Rep. Dis. (1975) 111(3):313-320.
102. MCLAUGHLIN VV, GENTHNER DE, PANELLA MM, RICH S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. (1998) 338(5):273-277.
103. MILLER SB: Prostaglandins in health and disease: an overview. Semin. Arthritis Rheum. (2006) 36(1):37-49.
104. SPANNHAKE EW, HYMAN AL, KADOWITZ PJ: Bronchoactive metabolites of arachidonic acid and their role in airway function. Prastaglandins (1981) 22(6):1013-1026.
105. GILES H, LEFF P: The biology and pharmacology of PGD2. Prostaglandins (1988) 35(2):277-300.
106. BHAGWAT SS, HAMANN PR, STILL WC, BUNTING S, FITZPATRICK FA: Synthesis and structure of the platelet aggregation factor thromboxane A2. Nature (1985) 315(6019):511-513.
107. POURIAN MR, KVIST U, BJORNDAHL L, OLIW EH: Rapid and slow hydroxylators of seminal E Prostaglandins among men in barren unions. Andrologia (1995) 27(2):71-79.
108. OLIW EH, FABIANI R, JOHANSSON L, RONQUIST G: Arachidonic acid 5-lipoxygenase and traces of E Prostaglandins in purified human prostasomes. J. Reprod. Fertil. (1993) 99(1):195-199.
109. IMIG JD: Eicosanoids and renal vascular function in diseases. Clin. Sci. (london) (2006) 111(1):21-34.
110. REARDON G, SCHWARTZ GF, MOZAFFARI E: Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin. Ther. (2003) 25(4):1172-1185.
111. SINGH GK, FONG LV, SALMON AP, KEETON BR: Chrome congestive heart failure. Study of low dosage prostaglandin-usages and complications. Eur. Heart J. (1993) 15(3):377-381.
112. OLLEY PM, COCEANIF, BODACH E: E-type Prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation (1976) 53(4):728-731.
113. GYIRES K: Gastric mucosal protection: from Prostaglandins to gene-therapy. Curr Med. Chem. (2005) 12(2):203-215.
114. GIBBS JSR. Recommendations on the management of pulmonary hypertension in clinical practice. Heart(2001) 86(Suppl. 1):11-113.
115. KAUFMAN MB, EL-CHAAR GM: Bone and tissue changes following prostaglandin therapy in neonates. Ann. Pharmacother. (1996) 30(3):269-274.
116. CATTRAL MS, ALTRAIF I, GREIG PD, BLENDIS L, LEVY GA: Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. Am. J. Med. (1994) 97(4):369-373.
117. CALDER AA: Prostaglandins as therapy for labour induction or therapeutic abortion. Reprod. Fert. Develop. (1990) 2(5):553-556.